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Abstract: Prostate cancer is a common human malignancy with few effective therapeutic 
options for treating advanced castration-resistant disease. The potential therapeutic effectiveness 
of immunotherapy and vaccines, in particular, has gained popularity based on the identification 
of prostate-associated antigens, potent expression vectors for vaccination, and data from recent 
clinical trials. A modified vaccinia Ankara (MVA) virus expressing 5T4, a tumor-associated 
glycoprotein, has shown promise in preclinical studies and clinical trials in patients with col-
orectal and renal cell carcinoma. This review will discuss the rationale for immunotherapy 
in prostate cancer and describe preclinical and limited clinical data in prostate cancer for the 
MVA-5T4 (TroVax®) vaccine.
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Introduction
Prostate cancer is the second most common malignancy and the sixth most common 
cause of cancer-related mortality worldwide.1 The natural history of early diagnosed 
clinically localized prostate cancer is indolent in the majority of men, with up to 80% 
having 20-year progression-free survival without local treatment.2 The men who 
develop advanced-stage disease, characterized by distant metastasis, initially undergo 
a hormone-sensitive period of growth when tumor cell proliferation is dependent on 
androgen stimulation. The use of androgen deprivation therapy (ADT) is beneficial 
during this stage of the disease, but management becomes more challenging as tumors 
evolve to become hormone refractory. New therapeutic options are needed, especially 
for patients with hormone-resistant tumors.
The terms “hormone-refractory prostate cancer” or “castration-resistant prostate 
cancer” (CRPC) are used interchangeably to describe prostate adenocarcinoma that pro-
gresses despite ADT, resulting in serum testosterone levels below a certain threshold, 
typically 20–50 ng/dL.3 The definition of when a patient becomes castration resistant 
can vary and has a distinct impact on the expected median survival. Although, his-
torically, median survival of 12–18 months could be expected for men with CRPC,4 
a more contemporary report using the first biochemical evidence of progression as the 
starting point quotes median survivals of 40–68 months, depending on the presence 
or absence of skeletal metastasis.5 Elevated serum prostate-specific antigen (PSA), 
lactate dehydrogenase, and alkaline phosphatase, as well as the presence of visceral 
metastasis, anemia, and low performance status, have been shown to portend decreased 
survival in these men.6OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Although there exists heterogeneity in defining survival, 
progression in CRPC is perhaps more prone to variability.7,8 
The Response Evaluation Criteria In Solid Tumors (RECIST) 
measure progression radiographically with solid tumor 
dimensions, but they do not take into account bone scan-
detected lesions, abnormal biochemistry, or the quality of life 
manifestations of metastatic prostate cancer.9 The Prostate 
Cancer Working Group (PCWG) was created in an effort to 
define clinical trial endpoints that are more specific for pros-
tate cancer, and has expanded the definitions of progression 
to include quality of life and PSA levels.10
Using any definition, the situation remains that there are 
few effective therapeutic options for CRPC. Several cytotoxic 
medications have been studied, with docetaxel, which is cur-
rently the first-line therapy, demonstrating a statistically sig-
nificant (but clinically modest) benefit in PSA response, pain 
control, improvement in quality of life, and increased median 
survival.11,12 The TAX 327 trial reported that docetaxel every 
3 weeks produced a 2.4-month increased median survival 
over mitoxantrone and had a 0.76 hazard ratio (HR) for death. 
Subsequent trials with satraplatin failed to demonstrate any 
benefit over placebo,13 and the addition of gemcitabine to 
docetaxel failed to show any benefit over docetaxel alone.14 
Recently, cabazitaxel has shown to have significant activity 
against CRPC in a Phase III trial. Carbazitaxel extended 
both median and progression-free survival in men who either 
progressed during or completed a docetaxel-based treat-
ment regimen compared with mitoxantrone.15 Abiraterone 
acetate, a hormonal agent that irreversibly inhibits CYP17, 
has shown antitumor activity in docetaxel-treated patients 
in a Phase II trial.16 Recent Phase III data indicate that this 
agent provides a PSA response as well as a 3.9-month sur-
vival benefit (P , 0.001) over placebo.17 These promising 
results will likely lead to US Food and Drug Administration 
(FDA) approval of this agent in the near future. Additional 
classes of agents currently undergoing study in CRPC include 
inhibitors of angiogenesis, growth factors, and endothelin. 
A comprehensive review of these agents may be found in a 
recent review by Nabhan et al.18
The role the immune system plays in tumor progression 
and containment is a topic of intense study and has provided 
a variety of therapeutic strategies for many cancers, including 
CRPC. Case reports of spontaneous regression of both liquid 
and solid human malignancies have supported hypotheses of 
antitumor host immune surveillance, and more recent experi-
mental data in murine models have confirmed that tumor 
immune surveillance is mediated by cytotoxic lymphocytes 
and interferon-γ production.19 Further evidence supporting 
the potential for immunotherapy against human tumors comes 
from data on interleukin 2 (IL-2), a cytokine that is critical to 
the maturation and proliferation of natural killer (NK), CD4+, 
and CD8+ T lymphocytes. In murine models of human renal 
cell, gastric, and squamous cell carcinomas, IL-2 was found 
to directly inhibit tumor growth via IL-2 receptors expressed 
by tumor cells as well as indirectly through activation of 
antitumor host NK and T cell responses.20 High-dose IL-2 
and recombinant interferon-α have shown clinical efficacy 
in metastatic melanoma and renal cell carcinoma (RCC) and 
in the adjuvant therapy of stage III melanoma, respectively. 
High-dose IL-2 can induce durable complete responses in 
a small but consistent subset of patients.21 Furthermore, the 
combination of IL-2 with adoptive T lymphocytes has shown 
remarkable activity in metastatic melanoma, especially in 
the setting of host lymphodepletion.22 The importance of 
T lymphocytes in the development of metastasis has also 
been suggested in the murine melanoma model in which 
CD8+ T cell-depleted mice had reduced disseminated tumor 
cell dormancy.23
Prostate immunotherapy
The identification of tumor-associated antigens in prostate 
cancer cells provides the basis for development of antigen-
specific vaccination as a therapeutic approach to prostate 
cancer. Immunotherapy for prostate cancer has increas-
ingly moved to the forefront of study for CRPC since the 
FDA approval of sipuleucel-T (APC8015) in April 2010. 
Sipuleucel-T (Provenge®, Dendreon, Seattle WA) consists 
of autologous dendritic cells loaded with prostatic acid 
phosphatase linked to granulocyte-macrophage colony-
stimulating factor (GM-CSF). Phase III data from three 
trials demonstrated a survival benefit of approximately 
4 months compared with placebo.24–26 Another strategy in 
development utilizes a poxvirus prime/boost vaccine regimen 
wherein the viruses express the transgenes for PSA. In this 
strategy, a recombinant vaccinia virus encoding PSA is used 
as a priming vector, followed by boosting with recombinant 
fowlpox virus encoding PSA. Phase II data in patients with 
PSA recurrence after local therapy for prostate cancer and 
no evidence of metastatic disease reported a 45% freedom 
from PSA progression at 19 months. In addition, 46% of 
the men treated with the prime/boost vaccine regimen had 
an increase in PSA-reactive T cells, without evidence of an 
anti-PSA humoral response.27 Subsequently, in an effort to 
increase the potency of the T cell response, several T cell 
costimulatory molecules were added to the poxviral vectors, 
including B7.1, ICAM-1, and LFA-3 (designated TRICOM OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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[triad of costimulatory molecules]).28 In a Phase II study of 
men with CRPC, this vaccine system, PROSTVAC-VF®  (BN 
ImmunoTherapeutics, Inc., Mountain View, CA), increased 
median overall survival by 8.5 months over a control vector 
treatment group.29 These encouraging results need to be vali-
dated in a larger Phase III trial. Additional tumor-associated 
antigens undergoing early development include prostate-
specific membrane antigen,30 prostate stem cell antigen, and 
six-transmembrane epithelial antigen of the prostate.31 Clini-
cal trial data have yet to be reported with these antigens.
The immune response is highly regulated, and T cell 
activation is subject to homeostatic control through a series 
of costimulatory and coinhibitory molecules. Following 
engagement of the T cell receptor with its cognate peptide 
and major histocompatibility complex, the T cell receives a 
“second” or costimulatory signal through CD28, which binds 
to B7.1 and B7.2 on antigen-presenting cells. This second 
signal results in T cell proliferation and cytokine production. 
Shortly after activation, the cytotoxic T lymphocyte antigen 4 
(CTLA-4) is mobilized to the cell surface and binds to B7.1 
and B7.2 with higher affinity than CD28. CTLA-4 serves as 
a coinhibitory receptor, as signaling through CTLA-4 results 
in decreased cytokine production and inhibition of cell cycle 
stimulation. This provides a highly coordinated homeostatic 
mechanism for brief activation of T cells while avoiding 
prolonged stimulation and induction of autoimmunity. This 
pathway has also provided another approach for cancer 
immunotherapy. A human monoclonal antibody that targets 
CTLA-4 (ipilumimab) results in a blockade of the coinhibi-
tory signaling mediated by CTLA-4 and allows T cells to 
remain in an activated state for a longer period of time. In 
a recent three-arm randomized Phase III clinical trial, patients 
receiving ipilumimab alone (3 mg/kg) or administered with a 
gp100 peptide vaccine were compared with patients receiving 
gp100 peptide vaccine alone.32 Ipilumimab alone resulted in 
a significant improvement in overall survival compared with 
vaccine alone (10.1 months vs 6.4 months, HR for death 0.66, 
P = 0.003), and ipilumimab in combination with gp100 vac-
cine also demonstrated an improved overall survival when 
compared with vaccine alone (10.0 months vs 6.4 months, 
HR for death 0.68, P , 0.0001).32 This trial also reported a 
10%–15% grade 3 or 4 toxicity rate largely related to autoim-
mune events, including 14 (2.1%) mortalities, largely attrib-
uted to autoimmune colitis. Based on the results of this trial, 
the FDA approved ipilumimab for the treatment of metastatic 
melanoma in March 2011. Ipilulmimab is also being studied 
in prostate cancer. In a Phase I clinical trial, 24 patients with 
CRPC were treated with ipilumimab in a dose escalation 
manner (range 0.5–3 mg/kg) administered with subcutaneous 
GM-CSF. Treatment resulted in PSA responses in three of 
six patients treated at the highest dose level, and one patient 
had a partial response of visceral metastases.33
Allogeneic whole cell vaccines have also been studied in 
CRPC and offer the advantage of not needing to define spe-
cific antigens for vaccination. The GVAX platform utilizes 
irradiated allogeneic whole tumor cells transfected with the 
human GM-CSF gene. Although this agent showed PSA-
stabilizing activity in Phase I/II trials, two Phase III clinical 
trials were terminated early due to excessive mortality in the 
experimental treatment arm.34 The reason for this unexpected 
result is unclear, and further investigation will be needed to 
define the utility of this agent for CRPC.
The 5T4 antigen
Fetal placental tissue evades immunosurveillance and invades 
“host” tissues, which is biologic behavior also displayed 
by neoplasms. Oncofetal antigens have therefore been the 
subject of study as possible diagnostic or therapeutic targets 
for human cancers. 5T4 is a 72kD protein identified on the 
syncitiotrophoblastic epithelium of human placental tissue 
using a murine monoclonal antibody.35 5T4 is a cell surface 
glycoprotein that is expressed on a variety of human tumors, 
including breast, ovary, stomach, colorectal, nonseminoma-
tous testis, bladder, and clear cell RCC, whereas expression 
is absent on most normal human tissues and weak on some 
normal epithelia.36 In contrast to PSA, 5T4 is not cleaved and 
is typically not found circulating in the serum. In vitro stud-
ies demonstrated that cells transfected with 5T4 cDNA had 
disrupted cell–cell contact and increased motility, suggesting 
a role for this molecule in tumor metastasis.37 This was further 
supported by data demonstrating that increased 5T4 expres-
sion was correlated with tumor invasiveness in a variety of 
human cancers.38–40 5T4 is strongly expressed on the surface 
of most prostate adenocarcinoma cells. Thus, 5T4 is an ideal 
antigenic target, as 5T4 exhibits selective tumor cell expres-
sion, may be required for tumor progression, and does not 
exist in soluble (and potentially immunosuppressive) forms.
Modified vaccinia virus  
Ankara (MVA)
Modified vaccinia Ankara (MVA) is a vaccinia virus attenu-
ated by multiple passages through chick embryo fibroblasts.41 
MVA is attractive as a viral vector due to its proven safety 
record as an alternative vaccine against smallpox in immu-
nosuppressed hosts. In addition, it has poor replication in 
transformed human cell lines with limited cell–cell spread, OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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in part due to potent induction of type I interferon from 
human cells.42 Pox viruses such as MVA can be engineered 
to encode large amounts of transfected DNA, and provide 
immunogenicity due to the expression of a soluble IL-1-β 
receptor.43 The MVA vector was used to encode human 
5T4 for vaccination purposes and extensively evaluated in 
preclinical and clinical settings.
MVA-5T4 preclinical data
Recombinant MVA-expressing human 5T4 (MVA-h5T4; 
TroVax®, Oxford Biomedica, Oxford, UK) has shown both 
protective and therapeutic effects against tumors in murine 
models. Mice inoculated with three doses of MVA-h5T4 
developed humoral responses to h5T4. When these mice 
were challenged with B16-5T4 melanoma and CT26-5T4 
colorectal tumor cells, they had significantly fewer lung 
tumor nodules than the mice inoculated with vaccine and 
treatment controls (MVA-LacZ or phosphate buffered saline 
[PBS]).44 In an experiment designed to test MVA-5T4 for 
treatment efficacy against established tumors, mice were first 
injected with CT26-5T4 tumors then immunized with two 
doses of MVA-5T4. The mice treated with MVA-5T4 had a 
reduction in tumor burden compared with the MVA-LacZ- or 
PBS-treated controls.44 Interestingly, these experiments did 
show an immunoglobulin G antibody-mediated response, but 
there was no evidence of a CTL response.44 In a follow-up 
study using the CT26 tumor model, mice depleted of CD8+ 
T lymphocytes showed no reduction in antitumor effect 
mediated by MVA-5T4, whereas mice depleted of CD4+ 
T lymphocytes had a completely abrogated response. This 
suggested that the treatment effect of MVA-5T4 was CD4+ 
T cell dependent and antibody mediated.45
MVA-5T4 clinical data
Table 1 summarizes the clinical and immunologic results of 
clinical trials using TroVax® to date. TroVax® was admin-
istered to 22 patients with metastatic colorectal cancer in a 
Phase I trial that established its safety and immunogenicity. 
Fourteen of 17 evaluable patients had a measurable 5T4-
specific antibody response, and eight patients had a de novo 
5T4-specific cellular proliferation response.46 5T4-specific 
antibody titers significantly predicted time to progression but 
not overall survival (P = 0.08 for all patients and P , 0.05 in 
those who mounted a 5T4 antibody response).46 Although 
50% of the patients did have injection site erythema, there 
were no serious adverse events attributable to TroVax®.46 
These encouraging results supported the initiation of Phase 
II trials of TroVax® for cancer immunotherapy.
TroVax® was further evaluated in three Phase II trials 
for metastatic colorectal cancer. In the first study, MVA-
5T4 monotherapy was administered before and after surgi-
cal metastasectomy. There were no serious adverse events, 
and the serologic and cellular response rates were similar 
to those in the Phase I trial.47 Although this study was not 
designed to prospectively determine survival, a retrospective 
analysis found a correlation between 5T4 cellular prolifera-
tive responses and survival.47 Two trials combined MVA-
5T4 with multiagent chemotherapy, and both reported an 
increased magnitude and duration of 5T4-specific immune 
responses compared with the earlier trials.48,49 One trial found 
a significant correlation between 5T4 cellular response and 
progression based on RECIST criteria.50 These trials not only 
established the safety of the concurrent administration of 
multiagent chemotherapy but also suggested a benefit com-
pared with MVA-5T4 monotherapy after chemotherapy.
TroVax® has been extensively evaluated in patients with met-
astatic RCC. Three Phase II studies and one multi-institutional, 
randomized, prospective Phase III trial for metastatic RCC have 
combined TroVax® with low- and high-dose IL-2, interferon-α, 
and the multityrosine kinase inhibitor sunitinib. Collectively, 
these trials reported favorable safety data similar to the colorectal 
cancer trials.51–55 All of the Phase II trials found a significant 
association between 5T4-specific antibody responses and 
overall survival, and the low-dose IL-2 and TroVax® trial also 
reported an association between anti-5T4 antibody response 
and progression-free survival.51,53,54
TRIST (TroVax® Renal Immunotherapy Survival Trial) 
was the first Phase III study designed to establish the efficacy 
of TroVax® (MVA-5T4) in patients with RCC. In this study, 
patients were treated with IL-2, interferon-α, or sunitinib, 
according to investigator preference, and patients were then 
randomized to additional therapy with TroVax® or placebo. 
The vaccine was well tolerated but did not result in enhanced 
overall survival relative to placebo controls.55 However, 
several subgroup analyses were performed that identified 
patients for whom MVA-5T4 may be of benefit.   Specifically, 
patients with a favorable prognostic score receiving MVA-
5T4 and IL-2 had a survival benefit relative to placebo and 
IL-2 (HR 0.54).55 Furthermore, this study reconfirmed the 
Phase II finding that high anti-5T4 antibody responses are 
associated with improved survival.55 Another interesting 
finding was a trend toward improvement in survival for 
patients with a specific immune response surrogate score that 
included the 5T4-specific antibody titer, hemoglobin level, 
and hematocrit.56 This was developed by assessing various 
host parameters in 590 patients treated on the Phase III TRIST OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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clinical trial. The immune response surrogate was established 
as a linear combination of baseline 5T4-specific antibody 
titers, hemoglobin level, and hematocrit, which were the 
only variables to remain statistically associated with survival 
after adjustment for standard of care. The availability of a 
predictive surrogate for therapeutic responses could enable 
better patient selection for vaccine treatment. These data 
need further prospective validation.
MVA-5T4 clinical data in CRPC
TroVax® has been evaluated in an open-label Phase II 
trial in metastatic CRPC patients in which the vaccine 
was administered either alone or in combination with 
GM-CSF.57 The 27 patients evaluated all had progression 
by PSA, RECIST, or bone scan criteria, despite prior 
ADT and taxane therapy. Patients with a low performance 
status or autoimmune disease were excluded. Fourteen 
patients received TroVax® alone, and 13 patients received 
TroVax® and 12 cycles of GM-CSF. The study was pri-
marily designed to monitor safety and both antibody and 
cellular immunologic   endpoints. In addition, serum PSA, 
computed tomography (CT), and bone scan progression 
were measured. There were no grade 3 or 4 toxicities in 
either arm of the trial. The most common adverse event 
reported was injection site irritation. Of the 24 patients 
evaluable for measurement of immune response, all had 
anti-5T4 antibody responses, and nine of 24 had a positive 
5T4 ELISPOT assay response, without significant differ-
ences between the study arms.57 Overall, 15 of 27 patients 
had a period of PSA stabilization. Six patients had a 
decreased PSA velocity, and five patients in the TroVax® 
and GM-CSF arm had a transient 4-week decrease in PSA 
of 30% or more that was attributed to the GM-CSF, as no 
patients in the TroVax® alone arm had a PSA decline.57 
There were no objective responses based on CT or bone 
scans in either treatment arm. Interestingly, patients in 
the TroVax® alone arm had an increased time to progres-
sion (TTP) compared with the TroVax® and GM-CSF 
arm (4.05 months vs 2.1 months, P = 0.0125), which did 
reach statistical significance. This trend clearly needs to 
be explored further in larger studies.
At the time of publication, this trial had not met its median 
survival endpoint; however, a preliminary retrospective 
analysis was performed to correlate immunologic response 
with clinical progression. Patients with a positive 5T4 cellular 
response were found to have a significantly increased median 
TTP (5.6 months vs 2.3 months, P = 0.024) compared with 
patients who did not.57
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Trovax® for the treatment of CRPC
Although a Phase II trial evaluating TroVax® and 
docetaxel versus docetaxel alone for CRPC was terminated 
by its sponsor,58 a similar study began accrual in September 
2010.59 This trial, NCT01194960, was designed to evaluate 
the addition of TroVax® to 10 cycles of docetaxel on progres-
sion-free survival by RECIST and PCWG2 criteria at week 
37. Eligible patients will have demonstrable metastatic dis-
ease, will not have had prior chemotherapy, and will remain 
on ADT to keep serum testosterone under 50 ng/dL. The 
estimated final data collection date of this study is expected 
to be mid-2012.
MVA-5T4 for CRPC: future 
directions
TroVax® has now been widely evaluated in cancer patients 
with a variety of different cancers and in combination with 
several other agents. These studies have confirmed that 
vaccination is generally safe and feasible in patients with 
advanced cancers. To date, the evidence suggests that those 
patients who develop an immune response after vaccina-
tion, particularly a 5T4-specific antibody response, also 
exhibit improved therapeutic responses. Recent data in RCC 
showed that there was a correlation between several host 
factors (ie, hemoglobin level, hematocrit, and 5T4-specific 
antibody titers) and clinical response; this needs further 
validation in prospective trials and in other tumors.56
The use of TroVax® in combination with other therapies 
will also be important to further validate in larger series. 
There is increasing evidence that cytotoxic chemotherapy, 
radiation therapy, and possibly targeted therapy result in 
the release of tumor-associated antigens and can elicit an 
immune response. The addition of vaccines to patients with 
such antigen release may provide an additive and/or syner-
gistic approach to improve therapeutic responses to other 
therapeutic modalities. The optimal schedule, dosing, timing, 
and methods for monitoring responses are all areas that will 
need to be better evaluated and defined. Recent data from 
studies of ipilumimab have suggested that the kinetics of 
antitumor immunity may be very slow and missed by more 
standard RECIST criteria. This may be overcome by evaluat-
ing survival endpoints or using modified response criteria, 
such as the recently described immune response criteria, in 
which patients without clinically significant disease progres-
sion continue on immunotherapy until a definitive response 
is seen or clinically meaningful progression occurs.60
Although the clinical use of TroVax® for CRPC currently 
consists of a small number of patients, the   preliminary 
data regarding safety and immunologic responses are in 
line with those from the CRC and RCC literature. Due to 
the rather modest objective clinical responses of tumor 
vaccines, they are increasingly utilized as a component of 
combination therapy. The current Phase II trial for CRPC is 
following this trend by combining TroVax® with the current 
first-line therapy, docetaxel. These data are needed to further 
establish the safety and potential efficacy of the vaccine, 
which will need to be validated in a larger and prospective 
Phase III trial. In addition, the vaccine should be tested in 
combination with other agents demonstrating activity in 
CRPC, such as cabazitaxel and abiraterone, and other poten-
tial vaccine adjuvants, such as ipilumimab.
The selection of predictive biomarkers would be a major 
advance in the field and could help select the most appropri-
ate patients for inclusion in vaccine clinical trials. A larger 
number of patients with CRPC will allow such analyses to 
be performed. Future studies should include collection of 
prostate biopsy tissue, urine, and/or serum, when feasible, 
to assess various biomarkers that identify subgroups of 
patients that may benefit more from TroVax®.55,60 Potential 
biomarkers might include simple host factors as reported in 
RCC patients, serum markers (eg, cytokine, chemokines, 
vascular endothelial growth factor), immune gene poly-
morphisms, and single gene and genome-wide mutation 
analyses.
The modest therapeutic responses seen with current 
vaccines and other immunotherapeutic agents have shed 
light on the potential clinical benefit with immunotherapy. 
CRPC represents a logical tumor on which to focus, 
because vaccines have already shown promise for the 
disease, 5T4 expression is common, and vaccination is 
safe, has limited impact on quality of life, and may be 
combined with other regimens commonly employed in 
CRPC treatment, such as chemotherapy, radiation therapy, 
and hormone treatment. The future will depend on estab-
lishing well-designed clinical trials that incorporate more 
appropriate response criteria and correlative laboratory 
and immune response assays.
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